Researchers in Germany claim to have developed a nasal vaccine that effectively blocks the spread of Covid-19 by targeting its entry point into the body. The vaccine, made with a weakened but live form of the coronavirus, has shown promising results in early-stage trials conducted on hamsters.
In experiments, two doses of the vaccine were administered to hamsters and found to prevent the virus from replicating itself in their upper airways. This "sterilizing immunity" prevented illness in the animals and achieved a level of protection that is long-sought by researchers.
The vaccine works by boosting mucosal immunity, which is the body's defense against infections that occur on or near the surface of the skin - in this case, the nasal passages where the virus enters. The idea is to station "firefighters" underneath the smoke alarm of the nose to combat the infection early on.
While this approach has been around since the 1870s and was initially used for anthrax and rabies vaccines, scientists have now refined it to create a vaccine that can effectively target Covid-19 without causing serious harm.
The results are promising, with the hamster vaccine outperforming existing options in both human trials and animal studies. However, researchers caution that this is still an early stage of development and more testing needs to be conducted before it can be approved for widespread use.
Despite these reservations, experts say that a pan-coronavirus vaccine that induces mucosal immunity could be a game-changer in the fight against respiratory infections like Covid-19.
With several nasal vaccines already in late-stage trials or nearing completion, including those from China and India, researchers hope that this new approach will ultimately lead to more effective and longer-lasting protection against Covid-19.
In experiments, two doses of the vaccine were administered to hamsters and found to prevent the virus from replicating itself in their upper airways. This "sterilizing immunity" prevented illness in the animals and achieved a level of protection that is long-sought by researchers.
The vaccine works by boosting mucosal immunity, which is the body's defense against infections that occur on or near the surface of the skin - in this case, the nasal passages where the virus enters. The idea is to station "firefighters" underneath the smoke alarm of the nose to combat the infection early on.
While this approach has been around since the 1870s and was initially used for anthrax and rabies vaccines, scientists have now refined it to create a vaccine that can effectively target Covid-19 without causing serious harm.
The results are promising, with the hamster vaccine outperforming existing options in both human trials and animal studies. However, researchers caution that this is still an early stage of development and more testing needs to be conducted before it can be approved for widespread use.
Despite these reservations, experts say that a pan-coronavirus vaccine that induces mucosal immunity could be a game-changer in the fight against respiratory infections like Covid-19.
With several nasal vaccines already in late-stage trials or nearing completion, including those from China and India, researchers hope that this new approach will ultimately lead to more effective and longer-lasting protection against Covid-19.